Boundless Bio, Inc. (BOLD) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-01-26

Key Insights

David A. Hinkle, the Senior VP, Finance, Controller and Treasurer of Boundless Bio, Inc. (BOLD), has been granted a stock option to acquire 140,000 shares of the company's common stock.
The stock option has an exercise price of $1.26 and vests in 48 substantially equal monthly installments, with the first vesting on February 1, 2026.
This insider transaction suggests that Hinkle is confident in the company's future and aligns his interests with those of shareholders through this equity-based compensation.

Want the newest filings?

This analysis covers the filing from 2026-01-26. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-26

Zachary Hornby, the President and CEO of Boundless Bio, Inc., has been granted a stock option to acquire 600,000 shares of the company's common stock at an exercise price of $1.26 per share. This indicates management confidence in the company's future prospects.
The stock option vests over a 4-year period, with 1/48th of the shares vesting monthly, aligning Hornby's incentives with long-term shareholder value creation.
The filing does not indicate any other significant changes in Hornby's beneficial ownership, suggesting a stable leadership team and ownership structure.

Filed: 2026-01-26

Robert Doebele, the Chief Medical Officer of Boundless Bio, Inc. (BOLD), was granted a stock option to acquire 230,000 shares of the company's common stock on January 23, 2026.
The stock option has an exercise price of $1.26 per share and vests in 48 substantially equal monthly installments, with the first tranche vesting on February 1, 2026.
This stock option grant indicates the company's commitment to incentivizing and retaining its key executive talent, which is a positive sign for the company's long-term growth and success.

Filed: 2026-01-26

Christian Hassig, the Chief Scientific Officer of Boundless Bio, Inc., has been granted 230,000 stock options with an exercise price of $1.26 per share, vesting over 48 months.
The stock options were granted on January 23, 2026, indicating continued confidence in the company's leadership and long-term growth prospects.
The significant size of the stock option grant suggests Hassig's important role and influence within the company as a key executive.

Filed: 2026-01-26

The reporting person, Jessica Oien, was granted a stock option to purchase 220,000 shares of Boundless Bio, Inc. common stock at an exercise price of $1.26 per share, with a vesting period of 48 months.
This stock option award suggests that Oien, who holds the position of Chief Legal Officer and Corporate Secretary, has been granted an equity incentive as part of her compensation package to align her interests with those of the company and its shareholders.
The filing does not indicate any other transactions, such as open market purchases or sales of Boundless Bio shares, which could provide insights into Oien's overall investment thesis or sentiment towards the company.

Other reports for Boundless Bio, Inc.

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.